摘要
Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, the humanized mAb nimotuzumab </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with </span><span style="font-family:Verdana;">a more</span><span style="font-family:Verdana;"> than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">;1.1</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months fo
Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, the humanized mAb nimotuzumab </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with </span><span style="font-family:Verdana;">a more</span><span style="font-family:Verdana;"> than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">;1.1</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months fo
作者
Raiza Ruiz-Lorente
Sayly Alfonso
Eduardo Santiesteban
Yamilka Sánchez
Kirenia Camacho
Erasmo Mendoza
Carmen Elena Viada
Ramón Ortiz
Ihosvannys Carreño
Mayelin Troche
Meylan Cepeda
Ana Rosa Vals
Leticia Cabrera
Annia Gorte
Delmis Batista
Milagros Domenech
Yanela Santiesteban
Yuliannis Santiesteban
Daymys Estevez
Jessica García-Viamontes
Conrado Ramos Mico
Mayra Ramos-Suzarte
Raiza Ruiz-Lorente;Sayly Alfonso;Eduardo Santiesteban;Yamilka Sánchez;Kirenia Camacho;Erasmo Mendoza;Carmen Elena Viada;Ramón Ortiz;Ihosvannys Carreño;Mayelin Troche;Meylan Cepeda;Ana Rosa Vals;Leticia Cabrera;Annia Gorte;Delmis Batista;Milagros Domenech;Yanela Santiesteban;Yuliannis Santiesteban;Daymys Estevez;Jessica García-Viamontes;Conrado Ramos Mico;Mayra Ramos-Suzarte(González Coro Hospital, La Habana, Cuba;Celestino Hernández Robau Hospital, Villa Clara, Cuba;Jose Ramón Lopez Tabranes Hospital, Matanzas, Cuba;III Congreso Hospital, Pinar del Río, Cuba;Faustino Perez Hospital, Matanzas, Cuba;Center of Molecular Immunology, Havana, Cuba)
